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The objectives of treatment for children with central pre-
cocious puberty (CPP) are to avoid psychosocial problems
caused by early pubertal development and to normalize
adult height (AH). A long-acting GnRH analog is the
treatment of choice for CPP. GnRH analog administration
effectively arrests further development of secondary sex
characteristics, slows bone age (BA) maturation, increases
pubertal height gain, and is believed to eventually improve
AH prognosis. However, the improvement of AH is not
well established. It is reported that GnRH analog is effec-
tive to improve adult height only in early onset (girls <6
years) CPP [1]. Although BA maturation is decelerated by
suppressing gonadotropins with GnRH analog and puber-
tal period is elongated, growth rate diminishes due to sup-
pressed sex steroid hormone and, in part due to decreased
GH secretion.
For the evaluation of efficacy of GnRH analog for adult
height improvement, one problem is that the prediction
method for adult height in CPP is not established. It is
reported that predicted adult height (PAH) using the
Bayley-Pinneau table for accelerated BA overestimated
AH in untreated patients with CPP, and the PAH based
on the projected height SD score for BA is useful [2].
Most Asian countries use a starting dose of 100 µg/kg/
month of leuproride acetate depo [3]. During GnRH ana-
log treatment, serum concentrations of LH, testosterone
or estradiol should be monitored as well as pubertal
changes and bone age, height and height velocity. For
some older patients, a dose of up to 180 µg/kg/month of
leuproride acetate depo is necessary to suppress LH con-
centration less than 0.5 mIU/ml. When growth velocity is
decreased, possible options is to add growth hormone or
anabolic steroid hormone only in boys.
The decision to stop therapy should be individualized
and based on various factors such as growth velocity, bone
age, chronological age, predicted adult height, emotional
maturity, and patient’s wish.
After treatment discontinuation, long-term follow up is
recommended for adult height, reproductive function and
bone mineral density.
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